Brookfield Corp’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Brookfield Corp’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-55,201	Closed	-$5.02M	–	792
2023 Q1	$5.02M	Buy	+55,201	New	+$3.24M	0.02%	290

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brookfield Corp's RETA Position: Q2 2023 in Review

Brookfield Corp sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 55,201 shares — an estimated $5.02M sold.

Brookfield Corp first reported a position in RETA in Q1 2023 and held it in 1 quarter. The position peaked at $5.02M in Q1 2023. 213 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

Brookfield Corp reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Brookfield Corp sold 55,201 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $5.02M.
Brookfield Corp first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 1 quarter.
Brookfield Corp's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5.02M in Q1 2023.
213 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Brookfield Corp's 13F filing for Q2 2023, filed 14 Aug 2023.